Undeclared Drugs in Herbal Products: The NHP Adulteration Playbook

Health Canada issued a Type I recall on 25 August 2026 for two Twins Herbal products, Idakole and Pelorie, after testing found they contained undeclared sildenafil, a prescription drug. Neither product held a market authorization. For the people who bought them, the risk is real, because sildenafil can drop blood pressure dangerously when it is combined with nitrate heart medicines. For the natural health product industry, the recall points to something larger. Adulterated products that pose as herbal remedies are polluting the category that legitimate licence holders work inside, and Health Canada is escalating enforcement.

This article is not a consumer safety notice. It is written for NHP manufacturers, importers, and quality teams who need to keep undeclared drugs out of their own supply chains. We explain how adulteration reaches a finished product, why a Type I recall moves so fast, and the specific quality controls, identity and adulterant testing, defensible finished product specifications, risk tiered supplier qualification, and a rehearsed recall procedure, that protect both a licensed business and the market category it depends on.

Executive Summary

On 25 August 2026, Health Canada posted recall RA-82524, a Type I action against Twins Herbal Idakole and Twins Herbal Pelorie for undeclared sildenafil. The products carried no Drug Identification Number and no Natural Product Number, which means they were never assessed for safety, efficacy, or quality. The recall sits inside a steady pattern of unauthorized sexual enhancement and weight loss products found to contain undeclared sildenafil, tadalafil, and sibutramine. The lesson for licensed NHP companies is direct. The controls Health Canada expects, identity testing, adulterant screening, defensible finished product specifications, and qualified suppliers, are the same controls that keep a business off the recall list.

A Type I recall signals a reasonable probability of serious harm or death. The window to act is short and the distribution list must already be current.
Undeclared drugs usually enter through unqualified botanical or imported ingredient suppliers, not through the finished blend a company mixes itself.
Identity testing and adulterant screening on incoming materials and finished product is the control that actually catches a spiked ingredient.
Every authorized product in Canada carries an eight digit DIN, NPN, or DIN-HM. No number means no authorization and no legal sale.

What Health Canada Recalled, and Why It Matters

What happened: Health Canada recalled Twins Herbal Idakole and Twins Herbal Pelorie, two liquids distributed in Ontario with no market authorization, because they contained undeclared sildenafil. Why it matters: sildenafil is a prescription only drug with real cardiovascular risk, and a Type I classification means Health Canada judged a reasonable probability of serious harm. What to do: treat the recall as a template for the failures, no authorization, no identity testing, no supplier qualification, that expose any NHP business.

The recall record is specific. The recalling firm is Twins African Restaurant and Bar Inc. of Brampton, Ontario. The depth of recall is stated as retailers, and all lots of both liquids are affected. Sildenafil appears on Health Canada's Prescription Drug List, so a product that contains it can only be sold with a prescription and a proper drug authorization. Selling it inside an unauthorized herbal liquid is not a labelling slip. It places a potent vasodilator into the hands of consumers who have no way to know it is there, including people on nitrates for angina, for whom the interaction can be life threatening.

For a legitimate licence holder, the reputational damage is collateral. Every recall of a spiked pseudo herbal product feeds a public impression that the whole category is unregulated, when in fact authorized natural health products are licensed and manufactured under a defined framework. Understanding where that framework begins is the first step, and our overview of natural health product regulations in Canada sets out the licensing and site obligations that separate a compliant product from an unauthorized one.

Authorized, Unauthorized, and the DIN, NPN, DIN-HM Check

What it is: an authorized health product in Canada always carries an eight digit identifier that shows Health Canada has assessed it. An unauthorized product has no number and has been assessed by no one. Why it matters: the number is the fastest test a retailer, importer, or buyer can run before a product reaches a shelf. The table below shows what each identifier authorizes and where to verify it.

Identifier	What it authorizes	Governing regulations	Where to verify
DIN, eight digits	Pharmaceutical and non-prescription drugs	Food and Drug Regulations	Drug Product Database
NPN, eight digits	Natural health products	Natural Health Products Regulations	Licensed Natural Health Products Database
DIN-HM, eight digits	Homeopathic medicines	Natural Health Products Regulations	Drug Product Database and LNHPD
No number	Nothing. The product was not assessed by Health Canada	Unauthorized for sale	Do not sell or distribute

Both registers are public. You can confirm a drug in the Drug Product Database and a licensed natural health product in the Licensed Natural Health Products Database. A distributor that receives a botanical product with no number, or with a number that does not resolve to the exact product in front of them, has found a reason to stop, not a reason to proceed.

How Undeclared Drugs Reach a Finished Product

What it is: adulteration is the deliberate or negligent introduction of an undeclared substance, most often to make a product appear to work. Why it matters: it rarely happens in a company's own mixing tank. It arrives through the supply chain, which is exactly where an under resourced quality system is weakest.

The common routes are predictable. A botanical extract is spiked with a synthetic drug at source to guarantee a felt effect. A proprietary blend hides an undisclosed ingredient behind a trade secret claim. A contract manufacturer substitutes a cheaper material without telling the brand owner. An imported ingredient arrives with a certificate of analysis that was never independently confirmed. In each case the finished product is built on a raw material nobody truly controlled. Knowing whether an input is a raw material or a finished product also decides which site licence and which controls apply, a distinction we cover in raw material or finished NHP classification.

The Testing That Catches a Spiked Ingredient

What it is: two related testing disciplines. Identity testing confirms a material is what the label says. Adulterant screening looks for what should not be there at all. What to do: build both into your finished product specifications and your incoming material controls, and do not let a supplier certificate of analysis replace your own verification for high risk categories.

Identity testing for botanicals can use organoleptic and macroscopic checks, high performance thin layer chromatography, or DNA based methods for species confirmation. Adulterant screening for the sexual enhancement category means a targeted look for PDE-5 inhibitors and their analogues, sildenafil, tadalafil, vardenafil, and the many designed structures that try to evade a simple assay, usually by liquid chromatography with mass spectrometry. The point is that a general potency test will not find sildenafil unless someone thought to look for it. Your finished product specifications are where that decision is written down and made routine.

Health Canada sets these expectations in the Good manufacturing practices guide for natural health products, GUI-0158, whose version 4 came into force on 4 March 2026. It covers specifications, testing, reduced and rotational testing, and the evidence needed to rely on a supplier result rather than repeat it. Reduced testing is earned through data and a qualified supplier, not assumed, and we walk through the practical impact in our review of the GUI-0158 reset and the end of FSRNs.

Supplier Qualification for Botanical and Imported Ingredients

What it is: the structured process of deciding which suppliers you trust, how far you trust them, and what evidence keeps that trust current. Why it matters: botanical and imported ingredients are the highest risk inputs in the NHP world, and an undeclared drug almost always rides in on one of them.

A defensible programme tiers suppliers by risk, then matches the depth of oversight to the tier. A high risk botanical extract from a new overseas supplier earns identity and adulterant testing on every lot, a signed quality agreement, and an audit. A low risk excipient from a long qualified source may earn periodic verification. The mistake is treating every supplier the same, or accepting a certificate of analysis as proof when no one has ever confirmed the supplier can produce that certificate honestly. Our guide to supplier qualification programmes that survive an inspection sets out the risk tiering, quality agreements, and audit depth that hold up when Health Canada asks how you knew your inputs were clean.

Recall Readiness and the Type I Clock

What it is: the rehearsed capability to identify, contact, and retrieve affected product quickly. Health Canada classes recalls by how serious the hazard is, and Type I is the most urgent. Why it matters: a Type I recall runs on a short clock, and a firm without current distribution records and a tested procedure loses control of the timeline.

Recall class	What it means	Practical response
Type I	Reasonable probability that use will cause serious adverse health consequences or death	Immediate action and public communication
Type II	Use may cause temporary adverse health consequences, or serious harm is remote	Prompt action and targeted notification
Type III	Use is not likely to cause any adverse health consequence	Corrective action at lower urgency

The RA-82524 recall reached the retailer level, which means the firm needed to know who received the product and reach them fast. Most companies discover the gaps in their distribution records only during a live event, when there is no time to fix them. The fix is a rehearsal. A mock recall tests whether you can trace a lot forward to every customer and account for the quantity within your target time, before a real recall makes the test mandatory.

Compliance Checklist

Work through this list against your own programme. Each item is a control that an adulteration event tends to expose.

Confirm every finished product holds a valid NPN, DIN, or DIN-HM, and that the number resolves to the exact product.
Include identity testing for every botanical raw material in your specifications, using a method suited to the material.
Add targeted adulterant screening for high risk categories, especially sexual enhancement, weight loss, sport, and sleep products.
Risk tier your suppliers and match testing, quality agreements, and audit depth to each tier.
Verify certificates of analysis independently for new or high risk suppliers, rather than accepting them on trust.
Keep distribution records current so a lot can be traced forward to every customer within your recall target time.
Maintain a written recall procedure and run a mock recall at least once a year.
Align your site and quality system with GUI-0158 version 4, including the rules for reduced and rotational testing.
Train purchasing and receiving staff to reject any material with no authorization number or an unresolved certificate.

Common Mistakes

Testing potency but not identity. A potency assay confirms how much of an expected marker is present. It will not flag a synthetic drug that was never in your specification.
Trusting the certificate of analysis. A certificate is only as honest as the supplier who wrote it. For high risk inputs, verify before you rely.
Treating a proprietary blend as a shield. A trade secret claim does not remove your obligation to know and control every ingredient in your product.
Qualifying a supplier once and never again. Suppliers change sources, staff, and sites. Qualification is a cycle, not a one time event.
Discovering your distribution list during the recall. If the first real test of your traceability is a Type I event, you are already behind the clock.

Frequently Asked Questions

Why was a herbal product recalled for sildenafil in Canada?

Because it contained an undeclared prescription drug. Sildenafil is on Health Canada's Prescription Drug List. When a product marketed as herbal is found to contain it without any authorization, Health Canada can recall the product and, given the cardiovascular risk, classify the action as Type I, the most serious class.

How do I check whether a natural health product is authorized?

Look for an eight digit number. Licensed natural health products carry an NPN, homeopathic medicines carry a DIN-HM, and drugs carry a DIN. You can confirm each in Health Canada's Licensed Natural Health Products Database or Drug Product Database. No number means the product was never assessed and is not authorized for sale.

What testing catches an undeclared drug in a supplement?

Targeted adulterant screening, usually by liquid chromatography with mass spectrometry, looks for specific drug classes and their analogues, such as PDE-5 inhibitors in sexual enhancement products. It works alongside identity testing, which confirms the botanical material is the correct species. A routine potency assay alone will not detect a substance that is not in your specification.

What is a Type I recall and how serious is it?

A Type I recall is Health Canada's most serious class. It means there is a reasonable probability that using the product will cause serious adverse health consequences or death. It calls for immediate action and public communication, and it depends on the firm being able to trace and retrieve the product quickly.

How do NHP companies keep undeclared drugs out of their supply chain?

By controlling the inputs. That means risk tiered supplier qualification, identity and adulterant testing built into specifications, independent verification of certificates for high risk suppliers, and quality agreements that define what a supplier must disclose. The finished product is only as clean as the raw materials that went into it.

Does a proprietary blend excuse me from ingredient controls?

No. A proprietary blend can protect a formula from disclosure to competitors, but it does not reduce your legal and quality obligation to know, control, and be able to account for every ingredient in the product you place on the market.

How MFLRC Can Help

MF License and Regulatory Consultants works with natural health product manufacturers and importers on exactly the controls this recall exposes. We support NHP product and site licensing, finished product specification design, and identity and adulterant test method coordination through our quality and quality control services. We build risk tiered supplier qualification programmes, write recall SOPs, run mock recall simulations, and carry out GUI-0158 gap assessments so your quality system is defensible before an inspector or a recall tests it.

If your NHP relies on botanical or imported ingredients, an identity and adulterant testing review is the fastest way to keep an undeclared drug recall out of your future. It is also the clearest signal to Health Canada that your quality system is built to catch what matters.

Book a Supplier and Testing Review

Conclusion

The Twins Herbal recall is a small event with a large lesson. Adulterated products enter through weak supply chains and unassessed ingredients, and Health Canada is pulling them with its most serious recall class. A legitimate NHP business protects itself, and the reputation of its whole category, with the same disciplined controls in every case. Test identity. Screen for adulterants. Qualify the supplier. Specify the finished product. Rehearse the recall. Each control is ordinary on its own. Together they are the difference between a company that catches a problem and one that becomes a recall notice.